Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Ingelheim Pharmaceuticals Inc.

Division of Boehringer Ingelheim International GmbH
us.boehringer-ingelheim.com

Latest From Boehringer Ingelheim Pharmaceuticals Inc.

GSK Seeks To Halt Boehringer Promos That 'Denigrate' Effectiveness Of Ellipta, Diskus Inhalers

US FDA's wariness of taking enforcement action against Rx drug promotions may lead to more suits like GSK's. Complaint says healthcare providers are switching COPD patients to BI's Respimat inhaler in response to BI's marketing campaign.

Advertising, Marketing & Sales Legal Issues

Scrip Asks… What Does 2019 Hold For Biopharma? Part 2: Business Trends

What do biopharma leaders and experts expect for the coming year? Following on from therapeutic area insights in part 1, our interviewees consider the outlook for business trends, from M&A and financing to digital strategy, AI and organizational management.

Business Strategies Financing

Make The ‘Purple Book’ More Orange, US FDA Told At Biosimilars Hearing

Listing patent and exclusivity information for novel biologics, as is done in the ‘Orange Book’ for small molecules, would help inform biosimilar development, stakeholders say at hearing on facilitating biologic competition and innovation; AbbVie urges FDA to use the Purple Book to clarify the scope of interchangeability decisions.

 

Biosimilars Biologics

Make The ‘Purple Book’ More Orange, US FDA Told At Biosimilars Hearing

Listing patent and exclusivity information for novel biologics, as is done in the ‘Orange Book’ for small molecules, would help inform biosimilar development, stakeholders say at hearing on facilitating biologic competition and innovation; AbbVie urges FDA to use the Purple Book to clarify the scope of interchangeability decisions.

 

Biosimilars Biologics
See All

Company Information

UsernamePublicRestriction

Register